^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + MEN1611 (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations
Excerpt:
Tumors harboring PIK3CA mutations were significantly sensitive to CH5132799 in vitro and were remarkably regressed by CH5132799 in in vivo mouse xenograft models. In combination with trastuzumab, tumors disappeared in the trastuzumab-insensitive breast cancer model with the PIK3CA mutation.
DOI:
10.1158/1078-0432.CCR-10-2882
